07:16:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2023-11-22 Årsstämma 2024
2023-10-13 Bonusutdelning CHR 7.72
2023-10-12 Bokslutskommuniké 2023
2023-07-06 Kvartalsrapport 2023-Q3
2023-04-13 Kvartalsrapport 2023-Q2
2023-03-30 Extra Bolagsstämma 2023
2023-01-12 Kvartalsrapport 2023-Q1
2022-11-24 Ordinarie utdelning CHR 7.04 DKK
2022-11-23 Årsstämma 2023
2022-10-12 Bokslutskommuniké 2022
2022-07-07 Kvartalsrapport 2022-Q3
2022-04-06 Kvartalsrapport 2022-Q2
2022-01-13 Kvartalsrapport 2022-Q1
2021-11-25 Ordinarie utdelning CHR 6.54 DKK
2021-11-24 Årsstämma 2022
2021-10-14 Bokslutskommuniké 2021
2021-07-08 Kvartalsrapport 2021-Q3
2021-05-18 Bonusutdelning CHR 6.54
2021-04-15 Kvartalsrapport 2021-Q2
2021-01-14 Kvartalsrapport 2021-Q1
2020-11-26 Ordinarie utdelning CHR 0.00 DKK
2020-11-25 Årsstämma 2021
2020-10-08 Bokslutskommuniké 2020
2020-07-02 Kvartalsrapport 2020-Q3
2020-04-16 Kvartalsrapport 2020-Q2
2020-01-15 Kvartalsrapport 2020-Q1
2019-11-28 Ordinarie utdelning CHR 7.07 DKK
2019-11-27 Årsstämma 2020
2019-10-10 Bokslutskommuniké 2019
2019-07-03 Kvartalsrapport 2019-Q3
2019-04-03 Kvartalsrapport 2019-Q2
2019-01-17 Kvartalsrapport 2019-Q1
2018-11-30 Ordinarie utdelning CHR 6.47 DKK
2018-11-29 Årsstämma 2019
2018-10-15 Bokslutskommuniké 2018
2018-06-29 Bonusutdelning CHR 5.94
2018-06-28 Kvartalsrapport 2018-Q3
2018-04-11 Kvartalsrapport 2018-Q2
2018-01-12 Kvartalsrapport 2018-Q1
2017-11-29 Ordinarie utdelning CHR 6.33 DKK
2017-11-29 Årsstämma 2018
2017-11-28 Årsstämma 2018
2017-10-25 Bokslutskommuniké 2017
2017-07-11 Bonusutdelning CHR 5.64
2017-07-05 Kvartalsrapport 2017-Q3
2017-04-06 Kvartalsrapport 2017-Q2
2017-01-11 Kvartalsrapport 2017-Q1
2016-11-30 Ordinarie utdelning CHR 5.23 DKK
2016-11-29 Årsstämma 2017
2016-10-26 Bokslutskommuniké 2016
2016-07-05 Kvartalsrapport 2016-Q3
2016-04-07 Kvartalsrapport 2016-Q2
2016-01-14 Kvartalsrapport 2016-Q1
2015-11-27 Ordinarie utdelning CHR 4.70 DKK
2015-11-26 Årsstämma 2016
2015-10-21 Bokslutskommuniké 2015
2015-07-07 Bonusutdelning CHR 6.57
2015-07-01 Kvartalsrapport 2015-Q3
2015-04-09 Kvartalsrapport 2015-Q2
2015-01-21 Kvartalsrapport 2015-Q1
2014-11-28 Ordinarie utdelning CHR 3.77 DKK
2014-11-27 Årsstämma 2015
2014-10-22 Bokslutskommuniké 2014
2014-07-02 Kvartalsrapport 2014-Q3
2014-04-09 Kvartalsrapport 2014-Q2
2014-01-15 Kvartalsrapport 2014-Q1
2013-11-27 Bonusutdelning CHR 3.13
2013-11-27 Ordinarie utdelning CHR 3.13 DKK
2013-11-26 Årsstämma 2014
2013-10-23 Bokslutskommuniké 2013
2013-07-03 Kvartalsrapport 2013-Q3
2013-04-11 Kvartalsrapport 2013-Q2
2013-01-16 Kvartalsrapport 2013-Q1
2012-11-28 Ordinarie utdelning CHR 2.90 DKK
2012-11-27 Årsstämma 2013
2012-07-04 Kvartalsrapport 2012-Q3
2012-04-19 Kvartalsrapport 2012-Q2
2012-01-11 Kvartalsrapport 2012-Q1
2011-11-30 Ordinarie utdelning CHR 3.57 DKK
2011-11-29 Årsstämma 2012
2011-07-06 Kvartalsrapport 2011-Q3
2011-04-06 Kvartalsrapport 2011-Q2
2011-01-12 Kvartalsrapport 2011-Q1
2010-12-01 Ordinarie utdelning CHR 0.64 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Christian Hansen Holding är en global livsmedelskoncern. Bolagets affärsinriktning återfinns inom utveckling av enzymer och naturliga färger som används som tillsatser inom livsmedelsindustrin. En stor del inom verksamheten innefattar forskning och utveckling av goda bakterier som tillsätts i probiotikaprodukter. Bolaget grundades ursprungligen 1874 och har sitt huvudkontor i Hørsholm.
2023-01-12 08:03:00

January 12, 2023 – Company announcement no. 1

Solid Q1 supports the outlook for 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased by 17% supported by the organic growth and exchange rates, leading to an EBIT margin b.s.i. of 24.7%. In light of the Q1 performance we maintain our underlying target for the year but update the outlook to reflect current exchange rate levels.

We will maintain a clear and strong focus on executing on our targets for the financial year 2022/23 while preparing for the proposed merger with Novozymes, which offers an exciting opportunity to create a leading global biosolutions partner based on strong complementary technology platforms, highly dedicated employees and a customer-centric approach.”

Q1 2022/23 highlights

  • Revenue amounted to EUR 310 million, up 15% from EUR 268 million in Q1 2021/22.
  • Organic growth was 10% in Q1 2022/23 driven by a mix of volume and price growth. Food Cultures & Enzymes organic growth was 8% mainly driven by price initiatives, but with good volume growth above underlying markets. Health & Nutrition organic growth was 12% driven by volume. The Lighthouses (Bioprotection, Fermented Plant Bases, Plant Health and HMO) was impacted by timing of orders and delivered 4% organic growth combined in Q1, while the core businesses delivered 10% organic growth.
  • EBIT b.s.i. amounted to EUR 77 million, up 17% from EUR 65 million in Q1 2021/22. The increase was driven by a positive contribution from exchange rates and pricing initiatives, which was partly offset by a negative impact from higher input costs.
  • The EBIT margin b.s.i. was 24.7%, up from 24.4% in Q1 2021/22. The improved margin was due to a positive contribution from exchange rates, which was partly offset by continuing inflationary pressures, despite ongoing price initatives.
  • Free cash flow b.a.s.i. amounted to EUR 17 million, down from EUR 55 million last year, as the cash flow from operating activities b.a.s.i. was negatively impacted by a change in working capital and higher taxes paid.
  • On December 12, 2022 Chr. Hansen and Novozymes announced that the two companies had entered into an agreement to create a leading global biosolutions partner through a statutory merger. Work has been initiated to seek customary merger control and other regulatory approvals from relevant authorities, while the extraordinary  general meeting for shareholder approval is currently expected to be held in the first half of the calendar year 2023.

Outlook

The current exchange rate level for the EUR/USD stands at 1.07 versus 0.97 at the time of the initial 2022/23 outlook provided on October 12, 2022. To reflect the 10% depreciation of the USD we update the outlook for the year regarding the impact from exchange rates on revenue, EBIT margin b.s.i. and cashflow b.a.s.i. The expectations to the underlying business incl. organic growth, EBIT margin b.s.i. and cash flow b.a.s.i. net of exchange rates remain unchanged.

  • Organic revenue growth is expected in the range of 7-10% (unchanged)
  • Impact from exchange rates on revenue will be neutral (previously positive 5%)
  • EBIT b.s.i. is expected to grow in line with revenue (previously faster than revenue)
  • EBIT margin b.s.i. is expected to be 26-27% (previously 27-28%)
  • Free cash flow b.a.s.i. is expected to be around EURm 170-210 (previously EURm 190-230)

The outlook for 2022/23 is based on actual exchange rates until January 11, 2023, and for the remainder of the year assuming constant exchange rates at the current level of EUR/USD rate of 1.07. For further details on the outlook for 2022/23, please refer to page 10.

See attachment for full Q1 2022/23 interim report.

Contact details

Anders Mohr Christensen, VP Group Strategy & Investor Relations, +45 25 15 23 64

Cristina Rønde Hefting, Senior Investor Relations Manager, +45 40 72 12 24

About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends, we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.